Results 281 to 290 of about 387,985 (305)

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Lancet, The, 2023
Joseph F Merola, Philip J Mease, Yoshiya Tanaka   +2 more
exaly  

Human Interleukin 1 Inhibitors

1987
DAVID L. ROSENSTREICH, ADRIANA HAIMOVITZ, KATHRYN M. BROWN, ZENGHUA LIAO   +3 more
openaire   +1 more source

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Lancet Regional Health - Europe, The, 2022
Linda Davidson, Juul M P A Van Den Reek, Mariolina Bruno   +2 more
exaly  

Stimulation of Production of Interleukin-1 and an Interleukin-1 Inhibitor in Human Monocytes

Rheumatology, 1985
W.P. Arend, F.G. Joslin, R.J. Massoni
openaire   +1 more source

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Nature Medicine, 2020
Kurt A Schalper, Ming Zhou, Alice M Walsh   +2 more
exaly  

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

European Journal of Medicinal Chemistry, 2023
Hong-Min Liu
exaly  

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Ca-A Cancer Journal for Clinicians, 2011
Timothy A Yap, Johann Sebastian de Bono
exaly  

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer

Ca-A Cancer Journal for Clinicians, 2005
Ruth M O'regan
exaly  

Angiogenesis Inhibitors: Current Strategies and Future Prospects

Ca-A Cancer Journal for Clinicians, 2010
Kristina M Cook, William D Figg
exaly